|
|
Vaccine Detail
|
V-01-351/V-01D Bivalence Vaccine |
| Vaccine Information |
- Vaccine Name: V-01-351/V-01D Bivalence Vaccine
- Target Pathogen: SARS-CoV-2
- Target Disease: COVID-19
- Manufacturer: Livzon Pharmaceutical Group Inc.
- Vaccine Ontology ID: VO_0005412
- Type: Subunit vaccine
- Status: Licensed
- Host Species for Licensed Use: Human
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Baboon Response
- Efficacy: In particular, V-01D-351 booster showed the highest pseudovirus neutralizing antibody titers against prototype SARS-CoV-2, Delta and Omicron BA.1 strains at day 14 post boosting, with GMTs 22.7, 18.3, 14.3 times higher than ICV booster, 6.2, 6.1, 3.8 times higher than V-01 booster (10 μg), and 5.2, 3.8, 3.5 times higher than V-01 booster (25 μg), respectively (Zhang et al., 2022).
|
| References |
Zhang et al., 2022: Zhiren Zhang 1, Qiaren He 2, Wei Zhao 1, Yong Li 1, Jiaming Yang 3, Zhenxiang Hu 3, Xi Chen 3, Hua Peng 4, Yang-Xin Fu 5, Long Chen 2, Ligong Lu 1. A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains. . ; ; . [PubMed: 35887928].
|
|
